Minapharm Pharmaceuticals (CAI:MIPH) FCF Margin %: -3.24% (As of Dec. 2025)


CAI:MIPH Minapharm Pharmaceuticals CAI:MIPH
41 GF Score
Price E£698.08
GF Value E£362.31
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Minapharm Pharmaceuticals FCF Margin %?

Minapharm Pharmaceuticals CAI:MIPH -0.27% 41 FCF Margin % is -3.24% as of Dec. 2025. GuruFocus rates CAI:MIPH with a GF Score™ of 41/100 and a GF Value™ of E£362.31 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 963 Drug Manufacturers companies, Minapharm Pharmaceuticals ranks worse than 67.6% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Minapharm Pharmaceuticals's Free Cash Flow for the three months ended in Dec. 2025 was E£-52 Mil. Minapharm Pharmaceuticals's Revenue for the three months ended in Dec. 2025 was E£1,598 Mil. Therefore, Minapharm Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2025 was -3.24%.

As of today, Minapharm Pharmaceuticals's current FCF Yield % is -3.97%.

The historical rank and industry rank for Minapharm Pharmaceuticals's FCF Margin % or its related term are showing as below:

CAI:MIPH' s FCF Margin % Range Over the Past 10 Years
Min: -33.48   Med: -16.59   Max: -5.08
Current: -5.08


During the past 5 years, the highest FCF Margin % of Minapharm Pharmaceuticals was -5.08%. The lowest was -33.48%. And the median was -16.59%.

CAI:MIPH's FCF Margin % is ranked worse than
67.6% of 963 companies
in the Drug Manufacturers industry
Industry Median: 2.51 vs CAI:MIPH: -5.08


Minapharm Pharmaceuticals FCF Margin % Related Terms


Minapharm Pharmaceuticals FCF Margin % Historical Data

* Premium members only.

The historical data trend for Minapharm Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minapharm Pharmaceuticals FCF Margin % Chart

Minapharm Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
-6.07 -16.59 -33.48 -17.43 -5.08

Minapharm Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.97 -12.43 11.91 -18.75 -3.24

CAI:MIPH vs ZTS, UTHR, VTRS: FCF Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Minapharm Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Minapharm Pharmaceuticals FCF Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Minapharm Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Minapharm Pharmaceuticals's FCF Margin % falls into.


CAI:MIPH
41GF Score
Minapharm Pharmaceuticals CAI:MIPH
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minapharm Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Minapharm Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-326.932/6438.177
=-5.08 %

Minapharm Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-51.851/1598.112
=-3.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -3.24% mean?
Minapharm Pharmaceuticals (CAI:MIPH) has a FCF Margin % of -3.24% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Minapharm Pharmaceuticals and its competitors. According to the industry distribution chart, Minapharm Pharmaceuticals ranks #651 out of 963 companies in the Drug Manufacturers industry, placing it in the top 67.6%.
Is Minapharm Pharmaceuticals' FCF Margin % too high?
Minapharm Pharmaceuticals' current FCF Margin % is -3.24%. Based on the distribution chart, Minapharm Pharmaceuticals ranks #651 out of 963 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Minapharm Pharmaceuticals has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Minapharm Pharmaceuticals ranks #651 out of 963 companies for FCF Margin %. This places Minapharm Pharmaceuticals in the lower half of its industry. The industry median FCF Margin % is 2.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Minapharm Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minapharm Pharmaceuticals's current FCF Margin % is -3.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£362.31, compared to a current price of E£698.08 — trading 92.7% above its estimated fair value. The current FCF Margin % is -3.24%. Minapharm Pharmaceuticals' overall GF Score™ is 41/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current FCF Margin % is -3.24% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?

Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued. The current stock price of E£698.08 is trading 92.7% above its estimated GF Value™ of E£362.31. GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CAI:MIPH:

  • FCF Margin %: -3.24%
  • GF Value™: E£362.31 vs. price of E£698.08 (92.7% above fair value)
  • GF Score™: 41/100 with 10 warning signs

No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Minapharm Pharmaceuticals Business Description

Address El-Bardissi Street, 2T Takseem Asmaa Fahmy Street, Heliopolis, Cairo, EGY
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
41GF Score

Get the complete analysis for CAI:MIPH

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£698.08
Price
E£362.31
GF Value